Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
CA 2534675 C · Owner: Stalder, Henri · Inventors: Nettekoven, Matthias Heinrich; Jolidon, Synese; Stalder, Henri
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses pain, neurodegenerative disfunction in memory and learning schizophrenia, dementia , and other diseases in which cognitive processes are impaired such as , attention deficit disorders or Alzheimer's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 2, 2004 and granted July 23, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 2, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 2, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.